COHEN & STEERS INC (CNS) Stock Fundamental Analysis
NYSE:CNS - New York Stock Exchange, Inc. - US19247A1007 - Common Stock - Currency: USD
Taking everything into account, CNS scores 6 out of 10 in our fundamental rating. CNS was compared to 233 industry peers in the Capital Markets industry. CNS scores excellent on profitability, but there are some minor concerns on its financial health. CNS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CNS was profitable.
CNS had a negative operating cash flow in the past year.
CNS had positive earnings in each of the past 5 years.
In the past 5 years CNS always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of CNS (18.81%) is better than 98.28% of its industry peers.
CNS's Return On Equity of 30.93% is amongst the best of the industry. CNS outperforms 95.28% of its industry peers.
The Return On Invested Capital of CNS (20.82%) is better than 97.42% of its industry peers.
CNS had an Average Return On Invested Capital over the past 3 years of 28.30%. This is significantly above the industry average of 7.84%.
The 3 year average ROIC (28.30%) for CNS is well above the current ROIC(20.82%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.81% | ||
| ROE | 30.93% | ||
| ROIC | 20.82% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
The Profit Margin of CNS (29.68%) is better than 73.82% of its industry peers.
CNS's Profit Margin has declined in the last couple of years.
CNS's Operating Margin of 33.60% is fine compared to the rest of the industry. CNS outperforms 60.52% of its industry peers.
CNS's Operating Margin has declined in the last couple of years.
CNS has a better Gross Margin (88.86%) than 92.27% of its industry peers.
CNS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.6% | ||
| PM (TTM) | 29.68% | ||
| GM | 88.86% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
CNS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CNS has more shares outstanding
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.28 indicates that CNS is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.28, CNS belongs to the top of the industry, outperforming 92.27% of the companies in the same industry.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.28 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.80 indicates that CNS may have some problems paying its short term obligations.
CNS has a Current ratio of 0.80. This is in the lower half of the industry: CNS underperforms 66.09% of its industry peers.
A Quick Ratio of 0.80 indicates that CNS may have some problems paying its short term obligations.
With a Quick ratio value of 0.80, CNS is not doing good in the industry: 65.67% of the companies in the same industry are doing better.
The current and quick ratio evaluation for CNS is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.8 |
3. Growth
3.1 Past
CNS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.58%.
The Earnings Per Share has been growing slightly by 2.50% on average over the past years.
Looking at the last year, CNS shows a quite strong growth in Revenue. The Revenue has grown by 8.82% in the last year.
CNS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.
EPS 1Y (TTM)7.58%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%7.14%
Revenue 1Y (TTM)8.82%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%9.58%
3.2 Future
CNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.36% yearly.
Based on estimates for the next years, CNS will show a small growth in Revenue. The Revenue will grow by 7.94% on average per year.
EPS Next Y6.69%
EPS Next 2Y10.54%
EPS Next 3Y10.74%
EPS Next 5Y10.36%
Revenue Next Year5%
Revenue Next 2Y8.63%
Revenue Next 3Y7.61%
Revenue Next 5Y7.94%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 25.84, CNS can be considered very expensive at the moment.
62.66% of the companies in the same industry are cheaper than CNS, based on the Price/Earnings ratio.
CNS is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 21.51, which indicates a rather expensive current valuation of CNS.
CNS's Price/Forward Earnings is on the same level as the industry average.
CNS is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.76, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.84 | ||
| Fwd PE | 21.51 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than the industry average as 72.96% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.41 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)3.86
PEG (5Y)10.35
EPS Next 2Y10.54%
EPS Next 3Y10.74%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 3.18%. Purely for dividend investing, there may be better candidates out there.
CNS's Dividend Yield is comparable with the industry average which is at 8.10.
Compared to an average S&P500 Dividend Yield of 2.37, CNS pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.18% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of CNS decreased in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
77.43% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP77.43%
EPS Next 2Y10.54%
EPS Next 3Y10.74%
77
+0.51 (+0.67%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners59.52%
Inst Owner Change0%
Ins Owners22.52%
Ins Owner Change0.57%
Market Cap3.93B
Analysts48
Price Target87.72 (13.92%)
Short Float %6.68%
Short Ratio10.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.18% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP77.43%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.32%
Min EPS beat(2)-2.29%
Max EPS beat(2)-0.35%
EPS beat(4)1
Avg EPS beat(4)-1.1%
Min EPS beat(4)-2.29%
Max EPS beat(4)0.49%
EPS beat(8)2
Avg EPS beat(8)-0.99%
EPS beat(12)6
Avg EPS beat(12)0.97%
EPS beat(16)10
Avg EPS beat(16)3.04%
Revenue beat(2)1
Avg Revenue beat(2)-4.71%
Min Revenue beat(2)-11.33%
Max Revenue beat(2)1.91%
Revenue beat(4)2
Avg Revenue beat(4)-1%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)6.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.78%
PT rev (3m)-7.03%
EPS NQ rev (1m)2.03%
EPS NQ rev (3m)-6.79%
EPS NY rev (1m)2.15%
EPS NY rev (3m)-6.5%
Revenue NQ rev (1m)2.4%
Revenue NQ rev (3m)2.4%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.84 | ||
| Fwd PE | 21.51 | ||
| P/S | 7.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.73 | ||
| P/tB | 8.04 | ||
| EV/EBITDA | 20.41 |
EPS(TTM)2.98
EY3.87%
EPS(NY)3.58
Fwd EY4.65%
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS10.38
BVpS9.96
TBVpS9.58
PEG (NY)3.86
PEG (5Y)10.35
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.81% | ||
| ROE | 30.93% | ||
| ROCE | 27.12% | ||
| ROIC | 20.82% | ||
| ROICexc | 23.12% | ||
| ROICexgc | 25.32% | ||
| OM | 33.6% | ||
| PM (TTM) | 29.68% | ||
| GM | 88.86% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexcg growth 3Y-36.94%
ROICexcg growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score3
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 74.13% | ||
| Cap/Sales | 1.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.8 | ||
| Altman-Z | 8.28 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)7.58%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%7.14%
EPS Next Y6.69%
EPS Next 2Y10.54%
EPS Next 3Y10.74%
EPS Next 5Y10.36%
Revenue 1Y (TTM)8.82%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%9.58%
Revenue Next Year5%
Revenue Next 2Y8.63%
Revenue Next 3Y7.61%
Revenue Next 5Y7.94%
EBIT growth 1Y11.24%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year16.8%
EBIT Next 3Y17.3%
EBIT Next 5Y16.09%
FCF growth 1Y-117.6%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-111.18%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%